secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2022-06-28T23:59:59+00:00
Accession:  0001104659-22-075050
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hepion appoints Anand Reddi and Kaouthar Lbiati to Board of Directors
---------------------------------------------------------------------

- Board expanded to 8; Reddi and Lbiati appointed independent directors effective June 27, 2022.
- Each receives $50,000 annual cash retainer and option to purchase 60,000 shares of common stock.
- Anand Reddi is VP at Adverum Biotechnologies; previously led international access at Gilead for HIV and hepatitis drugs.
- Kaouthar Lbiati is VP at Cytovia Therapeutics; held global leadership roles at Amgen, GSK, and Sanofi.
- Company is preparing rencofilstat for three Phase 2 trials in NASH and HCC and exploring partnering opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000110465922075050/0001104659-22-075050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000110465922075050/tm2219550d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-075050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer